These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 8289483)

  • 1. Binding of BCR/ABL junctional peptides to major histocompatibility complex (MHC) class I molecules: studies in antigen-processing defective cell lines.
    Cullis JO; Barrett AJ; Goldman JM; Lechler RI
    Leukemia; 1994 Jan; 8(1):165-70. PubMed ID: 8289483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peptides derived from the whole sequence of BCR-ABL bind to several class I molecules allowing specific induction of human cytotoxic T lymphocytes.
    Buzyn A; Ostankovitch M; Zerbib A; Kemula M; Connan F; Varet B; Guillet JG; Choppin J
    Eur J Immunol; 1997 Aug; 27(8):2066-72. PubMed ID: 9295046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intracellular transport of class I MHC molecules in antigen processing mutant cell lines.
    Anderson KS; Alexander J; Wei M; Cresswell P
    J Immunol; 1993 Oct; 151(7):3407-19. PubMed ID: 8376783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthetic peptide analogs derived from bcr/abl fusion proteins and the induction of heteroclitic human T-cell responses.
    Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Roberts W; Scheinberg DA
    Haematologica; 2005 Oct; 90(10):1324-32. PubMed ID: 16219568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunological characterization of the tumor-specific bcr/abl junction of Philadelphia chromosome positive chronic myeloid leukemia.
    Barrett J; Guimaraes A; Cullis J; Goldman JM
    Stem Cells; 1993 Oct; 11 Suppl 3():104-8. PubMed ID: 8298471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Binding of BCR/ABL junctional peptides to major histocompatibility complex (MHC) class I-B35 molecules: relationship between antigen defective cell lines and HLA frequencies in CML patients.
    Martinelli G; Zaccaria A; Saglio G; Zuffa E; Farabegoli P; Testoni N; Conte R; Tura S
    Leukemia; 1995 Oct; 9(10):1795-6. PubMed ID: 7564530
    [No Abstract]   [Full Text] [Related]  

  • 7. BCR-ABL fusion regions as a source of multiple leukemia-specific CD8+ T-cell epitopes.
    Kessler JH; Bres-Vloemans SA; van Veelen PA; de Ru A; Huijbers IJ; Camps M; Mulder A; Offringa R; Drijfhout JW; Leeksma OC; Ossendorp F; Melief CJ
    Leukemia; 2006 Oct; 20(10):1738-50. PubMed ID: 16932347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two brc-abl junction peptides bind HLA-A3 molecules and allow specific induction of human cytotoxic T lymphocytes.
    Greco G; Fruci D; Accapezzato D; Barnaba V; Nisini R; Alimena G; Montefusco E; Vigneti E; Butler R; Tanigaki N; Tosi R
    Leukemia; 1996 Apr; 10(4):693-9. PubMed ID: 8618449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules.
    Bocchia M; Wentworth PA; Southwood S; Sidney J; McGraw K; Scheinberg DA; Sette A
    Blood; 1995 May; 85(10):2680-4. PubMed ID: 7742526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peptides spanning the junctional region of both the abl/bcr and the bcr/abl fusion proteins bind common HLA class I molecules.
    Berke Z; Andersen MH; Pedersen M; Fugger L; Zeuthen J; Haurum JS
    Leukemia; 2000 Mar; 14(3):419-26. PubMed ID: 10720136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of HLA Class I and Class II genes with bcr-abl transcripts in leukemia patients with t(9;22) (q34;q11).
    Mundhada S; Luthra R; Cano P
    BMC Cancer; 2004 Jun; 4():25. PubMed ID: 15202948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of major histocompatibility complex class I interaction with Epstein-Barr virus and human immunodeficiency virus peptides by elevation of membrane H-2 and HLA in peptide loading-deficient cells.
    Stuber G; Modrow S; Höglund P; Franksson L; Elvin J; Wolf H; Kärre K; Klein G
    Eur J Immunol; 1992 Oct; 22(10):2697-703. PubMed ID: 1327802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peptide loading of empty major histocompatibility complex molecules on RMA-S cells allows the induction of primary cytotoxic T lymphocyte responses.
    De Bruijn ML; Schumacher TN; Nieland JD; Ploegh HL; Kast WM; Melief CJ
    Eur J Immunol; 1991 Dec; 21(12):2963-70. PubMed ID: 1660811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HLA-A2 molecules in an antigen-processing mutant cell contain signal sequence-derived peptides.
    Wei ML; Cresswell P
    Nature; 1992 Apr; 356(6368):443-6. PubMed ID: 1557127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Presentation of a horse cytochrome c peptide by multiple H-2b class I major histocompatibility complex (MHC) molecules to C57BL/6- and bm1-derived cytotoxic T lymphocytes: presence of a single MHC anchor residue may confer efficient peptide-specific CTL recognition.
    Sheil JM; Schell TD; Shepherd SE; Klimo GF; Kioschos JM; Paterson Y
    Eur J Immunol; 1994 Sep; 24(9):2141-9. PubMed ID: 7522163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune selection in murine tumors. Ph.d thesis.
    Svane IM; Engel AM
    APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of wild-type and mutant p53 peptides binding to HLA-A2 assessed by a peptide loading-deficient cell line assay and a novel major histocompatibility complex class I peptide binding assay.
    Stuber G; Leder GH; Storkus WT; Lotze MT; Modrow S; Székely L; Wolf H; Klein E; Kärre K; Klein G
    Eur J Immunol; 1994 Mar; 24(3):765-8. PubMed ID: 8125143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Presentation of viral antigens restricted by H-2Kb, Db or Kd in proteasome subunit LMP2- and LMP7-deficient cells.
    Zhou X; Momburg F; Liu T; Abdel Motal UM; Jondal M; Hämmerling GJ; Ljunggren HG
    Eur J Immunol; 1994 Aug; 24(8):1863-8. PubMed ID: 8056044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A viral peptide can mimic an endogenous peptide for allorecognition of a major histocompatibility complex class I product.
    Guimezanes A; Schumacher TN; Ploegh HL; Schmitt-Verhulst AM
    Eur J Immunol; 1992 Jun; 22(6):1651-4. PubMed ID: 1318201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The influence of class II HLA type on the lymphoproliferative response of normal donors to a bcr-abl fusion peptide.
    MacIntyre AR; Christmas SE; Clark RE
    Exp Hematol; 1996 Sep; 24(11):1307-11. PubMed ID: 8862441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.